Hinova Pharmaceuticals Inc. (688302)

Overview

Hinova Pharmaceuticals Inc. is a clinical-stage pharmaceutical company founded in 2013, primarily focused on the research, development, and production of innovative therapeutics targeted at cancers and metabolic syndromes. Leveraging cutting-edge technologies such as proteolysis targeting chimera (PROTAC) and deuteration, Hinova is at the forefront of creating novel drugs aimed at addressing some of the most challenging diseases. With its headquarters in Chengdu, China, the company brings together a robust pipeline of products in various stages of clinical trials, reflecting its commitment to advancing healthcare and treatment options for patients globally.

Products and Services

• HC-1119:

  Currently in phase III clinical trials, HC-1119 is a promising therapeutic candidate for patients with castration-resistant prostate cancer. This advanced stage of the product highlights Hinova Pharmaceuticals Inc.’s progress toward bringing innovative cancer treatments to market.

• HP501:

  In phase II clinical trials, HP501 is designed to treat hyperuricemia and gout. By focusing on these metabolic syndromes, Hinova addresses the critical need for new and effective treatments in managing and potentially curing these conditions.

• HP558:

  HP558 is in phase II clinical trials targeting the treatment of various late-stage cancers. This product represents Hinova’s commitment to expanding its cancer care portfolio, offering hope to patients battling with advanced cancer forms.

• HP518:

  An oral PROTAC drug, HP518 is currently in phase I clinical trials and focuses on overcoming drug resistance in AR-mutated prostate cancer. By solving the issue of drug resistance, Hinova showcases its innovative approach in the research and development of cancer therapeutics.